COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Summary

To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were authorized for use in the USA. Researchers will also assess whether the booster dosing with the Moderna COVID-19 vaccine is safe in patients with multiple myeloma, amyloidosis, or other blood cancers.

Timeline

Start

2021-08-17

Primary completion

2021-11-02

Completion

2021-11-02

Drugs

Indications